Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins …
Y Arad, R Ramakrishnan, HN Ginsberg - Journal of Lipid Research, 1990 - ASBMB
We investigated the metabolism of very low density lipoprotein (VLDL), intermediate density
lipoprotein (IDL), and low density lipoprotein (LDL) apolipoprotein B (apoB) in seven
patients with combined hyperlipidemia (CHL), using 125I-labeled VLDL and 131I-labeled
LDL and compartmental modeling, before and during lovastatin treatment. Lovastatin
therapy significantly reduced plasma levels of LDL cholesterol (142 vs 93 mg/dl, P less than
0.0005) and apoB (1328 vs 797 micrograms/ml, P less than 0.001). Before treatment, CHL …
lipoprotein (IDL), and low density lipoprotein (LDL) apolipoprotein B (apoB) in seven
patients with combined hyperlipidemia (CHL), using 125I-labeled VLDL and 131I-labeled
LDL and compartmental modeling, before and during lovastatin treatment. Lovastatin
therapy significantly reduced plasma levels of LDL cholesterol (142 vs 93 mg/dl, P less than
0.0005) and apoB (1328 vs 797 micrograms/ml, P less than 0.001). Before treatment, CHL …